Patrick Ray Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrick Ray Ng has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Alexander G. Yearley
Harvard Medical School, Boston, Massachusetts, USA
2 shared publicationsBrian V. Nahed
Harvard Medical School, Boston, Massachusetts, USA
2 shared publications- Brian Vala Nahed
Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA
2 shared publications - Michael A. Mooney
Harvard Medical School, Boston, Massachusetts, USA; Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA
2 shared publications Saksham Gupta
Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA
2 shared publicationsAdrian B Roth
Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (11) , 1170
Visual Neurorestoration: An Expert Review of Current Strategies for Restoring Vision in Humans
Visual impairment impacts nearly half a billion people globally. Corrective glasses, artificial lens replacement, and medical management have markedly improved the management of diseases inherent to the eye, such as refractive errors, cataracts, and glaucoma. However, therapeutic strategies for retinopathies, optic nerve damage, and distal optic pathways remain limited. The complex optic apparatus comprises multiple neural structures that transmit information from the retina to the diencephalon to the cortex. Over the last few decades, innovations have emerged to address the loss of function at each step of this pathway. Given the retina’s lack of regenerative potential, novel treatment options have focused on replacing lost retinal cell types through cellular replacement with stem cells, restoring lost gene function with genetic engineering, and imparting new light sensation capabilities with optogenetics. Additionally, retinal neuroprosthetics have shown efficacy in restoring functional vision, and neuroprosthetic devices targeting the optic nerve, thalamus, and cortex are in early stages of development. Non-invasive neuromodulation has also shown some promise in modulating the visual cortex. Recently, the first in-human whole-eye transplant was performed. While functional vision was not restored, the feasibility of such a transplant with viable tissue graft at one year was demonstrated. Subsequent studies are now focused on guidance cues for axonal regeneration past the graft site to reach the lateral geniculate nucleus. Although the methods discussed above have shown promise individually, improvements in vision have been modest at best. Achieving the goal of restoration of functional vision will clearly require further development of cellular therapies, genetic engineering, transplantation, and neuromodulation. A concerted multidisciplinary effort involving scientists, engineers, ophthalmologists, neurosurgeons, and reconstructive surgeons will be necessary to restore vision for patients with vision loss from these challenging pathologies. In this expert review article, we describe the current literature in visual neurorestoration with respect to cellular therapeutics, genetic therapies, optogenetics, neuroprosthetics, non-invasive neuromodulation, and whole-eye transplant.
- 30 October 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (11) , 1170
Open AccessVisual Neurorestoration: An Expert Review of Current Strategies for Restoring Vision in Humans
Visual impairment impacts nearly half a billion people globally. Corrective glasses, artificial lens replacement, and medical management have markedly improved the management of diseases inherent to the eye, such as refractive errors, cataracts, and glaucoma. However, therapeutic strategies for retinopathies, optic nerve damage, and distal optic pathways remain limited. The complex optic apparatus comprises multiple neural structures that transmit information from the retina to the diencephalon to the cortex. Over the last few decades, innovations have emerged to address the loss of function at each step of this pathway. Given the retina’s lack of regenerative potential, novel treatment options have focused on replacing lost retinal cell types through cellular replacement with stem cells, restoring lost gene function with genetic engineering, and imparting new light sensation capabilities with optogenetics. Additionally, retinal neuroprosthetics have shown efficacy in restoring functional vision, and neuroprosthetic devices targeting the optic nerve, thalamus, and cortex are in early stages of development. Non-invasive neuromodulation has also shown some promise in modulating the visual cortex. Recently, the first in-human whole-eye transplant was performed. While functional vision was not restored, the feasibility of such a transplant with viable tissue graft at one year was demonstrated. Subsequent studies are now focused on guidance cues for axonal regeneration past the graft site to reach the lateral geniculate nucleus. Although the methods discussed above have shown promise individually, improvements in vision have been modest at best. Achieving the goal of restoration of functional vision will clearly require further development of cellular therapies, genetic engineering, transplantation, and neuromodulation. A concerted multidisciplinary effort involving scientists, engineers, ophthalmologists, neurosurgeons, and reconstructive surgeons will be necessary to restore vision for patients with vision loss from these challenging pathologies. In this expert review article, we describe the current literature in visual neurorestoration with respect to cellular therapeutics, genetic therapies, optogenetics, neuroprosthetics, non-invasive neuromodulation, and whole-eye transplant.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (16) , OF1-OF10
Solid Stress Estimations via Intraoperative 3D Navigation in Patients with Brain Tumors
Purpose: Physical forces exerted by expanding brain tumors—specifically the compressive stresses propagated through solid tissue structures—reduce brain perfusion and neurologic function but heretofore have not been directly measured in patients in vivo. Solid stress levels estimated from tumor growth patterns are negatively correlated with neurologic performance in patients. We hypothesize that measurements of solid stress can be used to inform clinical management of brain tumors. Experimental Design: We developed an intraoperative technique to quantitatively estimate solid stress and brain replacement by the tumor. In 30 patients, we made topographic measurements of brain deformation through the craniotomy site with a neuronavigation system during surgical workflows immediately preceding tumor resection (<5 minutes in the operating room). Utilizing these measurements in conjunction with finite element modeling, we calculated solid stress within the tumor and brain and estimated the amount of brain tissue replaced, i.e., lost, by tumor growth. Results: Mean solid stresses were in the range of 10 to 600 Pa, and the amount of tissue replacement was up to 10% of the brain. Brain loss in patients delineated glioblastoma from brain metastatic tumors, and in mice, solid stress was a sensitive biomarker of chemotherapy response. Conclusions: We present in this study a quantitative approach to intraoperatively measure solid stress in patients that can be readily adopted into standard clinical workflows. Brain loss due to tumor growth is a novel mechanical-based biomarker that, in addition to solid stress, may inform personalized management in future clinical studies in brain cancer.
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (16) , OF1-OF10
Open AccessSolid Stress Estimations via Intraoperative 3D Navigation in Patients with Brain Tumors
Purpose: Physical forces exerted by expanding brain tumors—specifically the compressive stresses propagated through solid tissue structures—reduce brain perfusion and neurologic function but heretofore have not been directly measured in patients in vivo. Solid stress levels estimated from tumor growth patterns are negatively correlated with neurologic performance in patients. We hypothesize that measurements of solid stress can be used to inform clinical management of brain tumors. Experimental Design: We developed an intraoperative technique to quantitatively estimate solid stress and brain replacement by the tumor. In 30 patients, we made topographic measurements of brain deformation through the craniotomy site with a neuronavigation system during surgical workflows immediately preceding tumor resection (<5 minutes in the operating room). Utilizing these measurements in conjunction with finite element modeling, we calculated solid stress within the tumor and brain and estimated the amount of brain tissue replaced, i.e., lost, by tumor growth. Results: Mean solid stresses were in the range of 10 to 600 Pa, and the amount of tissue replacement was up to 10% of the brain. Brain loss in patients delineated glioblastoma from brain metastatic tumors, and in mice, solid stress was a sensitive biomarker of chemotherapy response. Conclusions: We present in this study a quantitative approach to intraoperatively measure solid stress in patients that can be readily adopted into standard clinical workflows. Brain loss due to tumor growth is a novel mechanical-based biomarker that, in addition to solid stress, may inform personalized management in future clinical studies in brain cancer.
- Top Cited PapersOpen Access
- 16 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (20) , eadp0532
Optimal focused ultrasound lesion location in essential tremor
Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is an effective treatment for medically refractory essential tremor. We investigate ablation sites and potential tracts associated with optimal tremor control and side effects based on the analysis of 351 cases from three international hospitals. Lesions were segmented on day 1 thin-cut T2 axial images, mapped to standard Montreal Neurological Institute space, and used to derive probabilistic maps and tracts associated with tremor improvement and side effects. Lesioning of a specific subregion within the ventral intermediate nucleus and the cerebellothalamic tract was associated with optimal tremor improvements. Some lesion locations and tracts were associated with differential side effects. Overlaps with the optimal tremor improvement sites accounted for variance in clinical improvements in out-of-sample cases. Efficacy of this location was further confirmed by test-retest cases that underwent two MRgFUS procedures. We identify and validate a target area for optimal tremor control and sites of avoidance associated with side effects.
- 16 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (20) , eadp0532
Top Cited PapersOpen AccessOptimal focused ultrasound lesion location in essential tremor
Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is an effective treatment for medically refractory essential tremor. We investigate ablation sites and potential tracts associated with optimal tremor control and side effects based on the analysis of 351 cases from three international hospitals. Lesions were segmented on day 1 thin-cut T2 axial images, mapped to standard Montreal Neurological Institute space, and used to derive probabilistic maps and tracts associated with tremor improvement and side effects. Lesioning of a specific subregion within the ventral intermediate nucleus and the cerebellothalamic tract was associated with optimal tremor improvements. Some lesion locations and tracts were associated with differential side effects. Overlaps with the optimal tremor improvement sites accounted for variance in clinical improvements in out-of-sample cases. Efficacy of this location was further confirmed by test-retest cases that underwent two MRgFUS procedures. We identify and validate a target area for optimal tremor control and sites of avoidance associated with side effects.
- 1 July 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 95 (1) , e34
In Reply: Neurological Surgery Residency Programs in the United States: A National Cross-Sectional Survey
- 1 July 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 95 (1) , e34
In Reply: Neurological Surgery Residency Programs in the United States: A National Cross-Sectional Survey
- 1 March 2024
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 140 (3) , 746-754
Cavernous venous malformations in and around the central nervous system. Part 2: Intradural
Cavernous venous malformations (CavVMs) account for a spectrum of lesions with a shared pathogenesis. Their anatomical location dictates their clinical features and surgical treatment. Extradural and dura-based CavVMs were discussed in Part 1 of this review. In this part, intradural CavVMs are discussed, encompassing malformations growing within the intradural space without direct dural involvement. In addition to classic intra-axial CavVMs, cranial nerve CavVMs, intraventricular CavVMs, and intradural extramedullary spinal CavVMs are discussed in this group, given the similar natural history and specific management challenges. Herein the authors focus on critical clinical aspects of and surgical management of these malformations based on their location and discuss optimal surgical approaches at each of these anatomical locations with illustrative cases. The commonalities of the natural history and surgical management that are dictated by anatomical considerations lend to a new location-based taxonomy for classification of CavVMs.
- 1 March 2024
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 140 (3) , 746-754
Cavernous venous malformations in and around the central nervous system. Part 2: Intradural
Cavernous venous malformations (CavVMs) account for a spectrum of lesions with a shared pathogenesis. Their anatomical location dictates their clinical features and surgical treatment. Extradural and dura-based CavVMs were discussed in Part 1 of this review. In this part, intradural CavVMs are discussed, encompassing malformations growing within the intradural space without direct dural involvement. In addition to classic intra-axial CavVMs, cranial nerve CavVMs, intraventricular CavVMs, and intradural extramedullary spinal CavVMs are discussed in this group, given the similar natural history and specific management challenges. Herein the authors focus on critical clinical aspects of and surgical management of these malformations based on their location and discuss optimal surgical approaches at each of these anatomical locations with illustrative cases. The commonalities of the natural history and surgical management that are dictated by anatomical considerations lend to a new location-based taxonomy for classification of CavVMs.
- 20 November 2023
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 94 (5) , 1001-1008
Price Transparency for Cervical Spinal Fusion Among High-Performing Spine Centers in the United States
BACKGROUND AND OBJECTIVES: As of January 1, 2021, all US hospitals are required by the Hospital Price Transparency Final Rule (HPTFR) to publish standard charges for all items and services, yet the state of price transparency for cervical spinal fusion is unknown. Here, we assess the nationwide price transparency landscape for cervical spinal fusion among high-performing spine centers in the United States. METHODS: In this cross-sectional economic evaluation, we queried publicly available price transparency websites of 332 “high-performing” spine centers, as defined by the US News and World Report. We extracted variables including gross charges for cervical spinal fusion, payor options, price reporting methodology, and prices relevant to consumers including listed cash prices and minimum and maximum negotiated charges. RESULTS: While nearly all 332 high-performing spine surgery centers (99.4%) had an online cost estimation tool, the HPTFR compliance rate was only 8.4%. Gross charges for cervical spinal fusion were accessible for 68.1% of hospitals, discounted cash prices for 46.4% of hospitals, and minimum and maximum charges for 10.8% of hospitals. There were large IQRs for gross charges ($48 491.98-$99 293.37), discounted cash prices ($26 952.25-$66 806.63), minimum charges ($10 766.11-$21 248.36), and maximum charges ($39 280.49-$89 035.35). There was geographic variability in the gross charges of cervical spinal fusion among high-performing spine centers within and between states. There was a significant association between “excellent” discharge to home status and lower mean gross charges. CONCLUSION: Although online cost reporting has drastically increased since implementation of the HPTFR, data reported for cervical spinal fusion remain inadequate and difficult to interpret by both providers and patients.
- 20 November 2023
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 94 (5) , 1001-1008
Price Transparency for Cervical Spinal Fusion Among High-Performing Spine Centers in the United States
BACKGROUND AND OBJECTIVES: As of January 1, 2021, all US hospitals are required by the Hospital Price Transparency Final Rule (HPTFR) to publish standard charges for all items and services, yet the state of price transparency for cervical spinal fusion is unknown. Here, we assess the nationwide price transparency landscape for cervical spinal fusion among high-performing spine centers in the United States. METHODS: In this cross-sectional economic evaluation, we queried publicly available price transparency websites of 332 “high-performing” spine centers, as defined by the US News and World Report. We extracted variables including gross charges for cervical spinal fusion, payor options, price reporting methodology, and prices relevant to consumers including listed cash prices and minimum and maximum negotiated charges. RESULTS: While nearly all 332 high-performing spine surgery centers (99.4%) had an online cost estimation tool, the HPTFR compliance rate was only 8.4%. Gross charges for cervical spinal fusion were accessible for 68.1% of hospitals, discounted cash prices for 46.4% of hospitals, and minimum and maximum charges for 10.8% of hospitals. There were large IQRs for gross charges ($48 491.98-$99 293.37), discounted cash prices ($26 952.25-$66 806.63), minimum charges ($10 766.11-$21 248.36), and maximum charges ($39 280.49-$89 035.35). There was geographic variability in the gross charges of cervical spinal fusion among high-performing spine centers within and between states. There was a significant association between “excellent” discharge to home status and lower mean gross charges. CONCLUSION: Although online cost reporting has drastically increased since implementation of the HPTFR, data reported for cervical spinal fusion remain inadequate and difficult to interpret by both providers and patients.
- 19 May 2023
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 27 (3) , 422-439
Biophysical Principles and Computational Modeling of Deep Brain Stimulation
- 19 May 2023
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 27 (3) , 422-439
Biophysical Principles and Computational Modeling of Deep Brain Stimulation
- 20 July 2022
- Published by Elsevier in World Neurosurgery
- Vol. 166, e551-e560
Utility of a Pilot Neurosurgical Operative Skills Boot Camp in Medical Student Training
- 20 July 2022
- Published by Elsevier in World Neurosurgery
- Vol. 166, e551-e560
Utility of a Pilot Neurosurgical Operative Skills Boot Camp in Medical Student Training
- Open Access
- 27 November 2021
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 3 (Supplement) , v4-v15
Surgical advances in the management of brain metastases
As the epidemiological and clinical burden of brain metastases continues to grow, advances in neurosurgical care are imperative. From standard magnetic resonance imaging (MRI) sequences to functional neuroimaging, preoperative workups for metastatic disease allow high-resolution detection of lesions and at-risk structures, facilitating safe and effective surgical planning. Minimally invasive neurosurgical approaches, including keyhole craniotomies and tubular retractors, optimize the preservation of normal parenchyma without compromising extent of resection. Supramarginal surgery has pushed the boundaries of achieving complete removal of metastases without recurrence, especially in eloquent regions when paired with intraoperative neuromonitoring. Brachytherapy has highlighted the potential of locally delivering therapeutic agents to the resection cavity with high rates of local control. Neuronavigation has become a cornerstone of operative workflow, while intraoperative ultrasound (iUS) and intraoperative brain mapping generate real-time renderings of the brain unaffected by brain shift. Endoscopes, exoscopes, and fluorescent-guided surgery enable increasingly high-definition visualizations of metastatic lesions that were previously difficult to achieve. Pushed forward by these multidisciplinary innovations, neurosurgery has never been a safer, more effective treatment for patients with brain metastases.
- 27 November 2021
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 3 (Supplement) , v4-v15
Open AccessSurgical advances in the management of brain metastases
As the epidemiological and clinical burden of brain metastases continues to grow, advances in neurosurgical care are imperative. From standard magnetic resonance imaging (MRI) sequences to functional neuroimaging, preoperative workups for metastatic disease allow high-resolution detection of lesions and at-risk structures, facilitating safe and effective surgical planning. Minimally invasive neurosurgical approaches, including keyhole craniotomies and tubular retractors, optimize the preservation of normal parenchyma without compromising extent of resection. Supramarginal surgery has pushed the boundaries of achieving complete removal of metastases without recurrence, especially in eloquent regions when paired with intraoperative neuromonitoring. Brachytherapy has highlighted the potential of locally delivering therapeutic agents to the resection cavity with high rates of local control. Neuronavigation has become a cornerstone of operative workflow, while intraoperative ultrasound (iUS) and intraoperative brain mapping generate real-time renderings of the brain unaffected by brain shift. Endoscopes, exoscopes, and fluorescent-guided surgery enable increasingly high-definition visualizations of metastatic lesions that were previously difficult to achieve. Pushed forward by these multidisciplinary innovations, neurosurgery has never been a safer, more effective treatment for patients with brain metastases.